NSE: LUPIN | BSE: 500257

Falling Comet

Download real time

1940.00 -11.20 (-0.57%)

877.3K NSE+BSE Volume

NSE 17 Oct, 2025 3:31 PM (IST)

88,611

Market Cap

High in industry

0.9

Beta 1Year

Low volatility

Lupin Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for LUPIN, BSE:500257 Lupin Ltd.

Lupin Ltd.

10 Jul 2024

1940.00

-0.57%

Launches critical for sustenance of turnaround

Sell: Lupin Ltd.

Target

ICICI Securities Limited

Lupin’s recent success in US (sales grew ~34% YoY in FY24) is driven by its better regulatory track record and traction in inhalation portfolio. Share of inhalation products has risen from 25% of US sales in FY22 (USD 185mn) to 40% in FY24
(USD 326mn) post the launch of gSpiriva. In India, growth had been subdued due to the discontinuation of in-licensed brands (contribution down from 15% in FY23 to 11% in Q4FY24).

Lupin Ltd. has an average target of 2326.00 from 8 brokers.

Lupin Ltd.

15 May 2024

1940.00

-0.57%

LUPIN LIMITED

Hold: Lupin Ltd.

Target

Geojit BNP Paribas

Lupin Ltd. is trading below all available SMAs

Lupin Ltd.

08 May 2024

1940.00

-0.57%

Niche product drives earnings growth

Neutral: Lupin Ltd.

Target

Motilal Oswal

Lupin (LPC) delivered in-line operational performance in 4QFY24. LPC ended
FY24 on a strong note, with INR198b in sales (up 19% YoY), EBITDA margin of
18% (up 750bp YoY) and PAT of INR19b (vs. INR4b YoY). LPC continues to
implement efforts toward building a complex product pipeline in inhalation,
injectables and ophthalmics.

Lupin Ltd. is trading below all available SMAs

Lupin Ltd.

08 May 2024

1940.00

-0.57%

Result Update:Lupin

Buy: Lupin Ltd.

Target

Axis Direct

We have BUY on the stock

Number of FII/FPI investors decreased from 987 to 970 in Sep 2025 qtr

Lupin Ltd.

08 May 2024

1940.00

-0.57%

Lupin (HOLD): Stable margins; higher tax weighs on PAT

Hold: Lupin Ltd.

Target

BOB Capital Markets Ltd.

LPC delivered a healthy operational performance in Q4 with largely in-line revenue/PAT; higher tax impacted net profit

Lupin Ltd. is trading below all available SMAs

Lupin Ltd.

07 May 2024

1940.00

-0.57%

Mixed Earnings; healthy pipeline of complex products to drive growth

Buy: Lupin Ltd.

Sharekhan

Lupin reported a mix set of earnings where sales were 4% below our estimates at Rs. 4,895 crore. EBITDA was 4% below our estimates at Rs. 997 crore, while adjusted PAT was in-line with our estimate of Rs. 561 crore.

Lupin Ltd. is trading below all available SMAs

Lupin Ltd.

24 Apr 2024

1940.00

-0.57%

Company Update:Lupin

Buy: Lupin Ltd.

Axis Direct

Niche product approvals and a strong pipeline of new drugs could drive Revenue/PAT CAGR by 10%/19.5% over FY24E-FY26E. We maintain our BUY rating with a Target Price of Rs 1,770/share.

Number of FII/FPI investors decreased from 987 to 970 in Sep 2025 qtr

Lupin Ltd.

15 Apr 2024

1940.00

-0.57%

gSpiriva on a healthy growth track, headwinds receding

Buy: Lupin Ltd.

Recommendation Target

Sharekhan

Lupin has recently received approval for a generic version of Oracea (Doxycycline Capsules) in the US market. The company has received approval for 40MG in the US, which is expected to have sales of $128 million in the US market. Lupin has a healthy pipeline of complex generic products in the US market which would aid the company in achieving quarterly US sales of $200-220 million.